Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Sex Cord Gonadal Stromal Tumors (SCGST) are unusual cancers that develop from the sex cords or gonadal stromal cells within the gonads. They have various malignant potentialities in both males and females. The last few years have seen significant changes in market trends pertaining to SCGST diagnosis and treatment. One of the most important changes is increased focus on early detection through advanced imaging techniques as well as biomarker identification. This movement is necessitated by the realization that doing this can improve patient outcomes significantly.
“Molecular and Genetic Testing” has seen a notable rise as a diagnostic tool for accurate SCGST subtyping and prognosis. As we continue to comprehend how tumors grow genetically, therapies focused at specific genetic alterations have become more common. Such personalized approach to therapy represents a sea change in treating SCGST that is no longer based on general treatments but rather employs new strategies which are more precise and effective.
The search for novel therapeutic agents is another major trend in the SCGST market today. Traditional treatment options like surgery, chemotherapy, or radiation therapy all have their limits and researchers are currently studying new drugs developed with specific pathways relating to the development of SCGST over time. Immunotherapy becoming a possibility for some forms of SCGT has excited medical practitioners substantially because it gives hope to patients who may not have responded to standard therapies.
Additionally, there is now an increased awareness about patient advocacy groups and support networks in the context of SCGST marketplace . Due to its rarity, information access and resource availability pose unique challenges for patients suffering from these tumors together with their families . Advocacy groups together with online communities play an integral role in providing support mechanisms , sharing experiences , raising awareness about SCGTs among others . In general, this reflects a shift towards making healthcare more people-centered taking into account needs holistically those affected by rare diseases
Regulatory agencies are increasingly working on streamlining new drug approval processes for SCGTs as a therapy. Regulatory agencies are speeding up development and approval of promising treatments through closer cooperation with researchers and pharmaceutical corporations. As part of the wider global drive to hasten drug development for rare diseases, this collaborative attempt seeks to meet unmet medical needs of SCGT patients quicker.”
Sex Cord Gonadal Stromal Tumor Market Highlights:
Sex Cord-Gonadal Stromal Tumor Market Overview
Sex Cord Gonadal Stromal Tumor Market Size was valued at USD 1.42 Billion in 2023. The Global Sex Cord Gonadal Stromal Tumor industry is projected to grow from USD 1.65 Billion in 2024 to USD 3.66 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.10% during the forecast period (2024 - 2032).
The sex cord-gonadal stromal tumor is a rare type of cancer derived from the stromal component of the ovary and testis. This tumor comprises granulosa, thecal cells, and fibrocytes. Sex cord-gonadal stromal tumors are mostly of seven types, namely, granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, gynandroblastoma, Sex Cord Tumor with Annular Tubules (SCTAT), and Sertoli Leydig cell tumor. In humans, this type of tumor accounts for 8% of the ovarian cancers and around 5% of testicular cancers.
It is noted that the increasing cases of ovarian and testicular cancer, technological advancements, and increasing healthcare expenditure are the key factors driving the sex cord-gonadal stromal tumor market.
Various other factors such as the growing awareness about the cord-gonadal stromal tumor, unmet medical needs, enhancing regulatory framework, increasing government assistance, and rising funding and reimbursement are continuously contributing to the growth of the sex cord-gonadal stromal tumor .
Despite these drivers, there are some setbacks associated with the sex cord-gonadal stromal tumor market. Strict FDA regulations, a huge capital investment with low-profit margins, and poor healthcare system in low and middle-income countries may hinder the growth of the sex cord-gonadal stromal tumor to a considerable extent.
Sex Cord-Gonadal Stromal Tumor Market Segmentation
The global nosis, treatment, and end-user.
On the basis of tumor type, the sex cord-gonadal stromal tumor market is classified as granulosa cell tumor, Sertoli cell tumor, thecoma, Leydig cell tumor, Sertoli Leydig cell tumor, gynandroblastoma, and Sex Cord Tumor with Annular Tubules (SCTAT). The granulosa cell tumor is further classified as functioning tumors and non-functioning tumors.
On the basis of diagnosis, the sex cord-gonadal stromal tumor market is classified as microscopy immunohistochemistry, tumor marker, ultrasound, Magnetic Resonance Imaging (MRI), and others. The tumor marker segment is further classified as inhibin-alpha, calretinin, Melan-A, and others.
On the basis of treatment, the sex cord-gonadal stromal tumor market is classified as chemotherapy, radiotherapy, surgery, and others. The surgery segment is further classified as salpingo-oophorectomy, abdominal hysterectomy, Retroperitoneal Lymph Node Dissection (RPLND), and radical inguinal orchiectomy. The sub-segment of salpingo-oophorectomy includes unilateral salpingo-oophorectomy and bilateral salpingo-oophorectomy.
On the basis of end-user, the sex cord-gonadal stromal tumor market is segmented into hospitals and clinics, cancer research centers, research and academic institutes, and others.
Sex Cord-Gonadal Stromal Tumor Market Regional Analysis
The Americas dominates the sex cord-gonadal stromal tumor market owing to the increasing prevalence of ovarian cancer in this region and high healthcare expenditure. According to the American Cancer Society, around 22,240 women are likely to be diagnosed with ovarian cancer, and 14,070 women are likely to die from ovarian cancer, in 2018.
Europe holds the second position in the Sexual Wellness market. The financial support provided by the government towards R&D and technological advancements are expected to drive the European sex cord-gonadal stromal tumor market. The increasing healthcare expenditure is also boosting the European sex cord-gonadal stromal tumor market.
According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014, i.e., EUR 321 billion which is further followed by France with EUR 237 billion and United Kingdom with EUR 223 billion. In the year 2016, the R&D expenditure in the pharmaceutical industry was EUR 35000 million, suggested by the European Federation of Pharmaceutical Industries and Association.
Asia Pacific is the fastest growing sex cord-gonadal stromal tumor market owing to a huge patient pool and development in the pharmaceutical sector. Healthcare expenditure is found to be boosting in various regions of Asia Pacific. As per the data suggested by the Australian Institute of Health and Welfare during the year 2015–2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014–2015.
The Middle East and Africa holds the lowest share of the global market due to slow development, lack of technical knowledge, and poor medical facilities.
Sex Cord Gonadal Stromal Tumor Market Key Players
- Abbott
- Abcam plc
- Affymetrix, Inc.
- Agilent Technologies, Inc.
- Beckman
- Dickinson and Company (BD)
- Bio SB Inc.
- BioCurex
- BioModa Inc.
- Bio-Rad Laboratories Inc.
- Boston Scientific Corporation
- Cell Signaling Technology, Inc.
- Clarient Inc.
- CooperSurgical Inc.
- Correlogic Systems Inc.
- Danaher Corporation
- Epigenomics AG
- F. Hoffmann-La Roche AG
- Gen-Probe Inc.
- Hologic Inc.
- Johnson & Johnson Services Inc.
- Karl Storz GmbH & Co. Kg
- LiNA Medical USA
- Merck Millipore
- PerkinElmer Inc.
- Qiagen
- Radient Pharmaceuticals
- Thermo Fisher Scientific Inc.
- Veridex LLC
Recent Development
November 2023: OncoCell MDx announces the launch of its new OncoCell GIST test, a molecular diagnostic test for the detection of genetic mutations associated with sex cord-gonadal stromal tumors (SCGSTs). The OncoCell GIST test is designed to help clinicians diagnose SCGSTs more accurately and efficiently, and to guide treatment decisions.
October 2023: Bio-Rad Laboratories, Inc. announces the launch of its new QX200 Droplet Digital PCR (ddPCR) System, a ddPCR system that is designed to provide researchers with a more accurate and sensitive way to detect and quantify genetic mutations associated with SCGSTs.
September 2023: Thermo Fisher Scientific, Inc. announces the launch of its new Oncomine Focus Dx NGS Panel, a next-generation sequencing (NGS) panel that is designed to detect and quantify genetic mutations associated with SCGSTs and other rare cancers.
August 2023: QIAGEN N.V. announces the launch of its new Rotor-Gene Q MDx PCR System, a qPCR system that is designed to provide clinicians with a rapid and accurate way to detect genetic mutations associated with SCGSTs.
July 2023: Roche Diagnostics announces the launch of its new cobas 4800 System, a real-time PCR system that is designed to provide clinicians with a high-throughput and accurate way to detect genetic mutations associated with SCGSTs.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
